| Serial Number | 90095313 |
| Word Mark | DUALASE |
| Filing Date | Wednesday, August 5, 2020 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, May 2, 2023 |
| Registration Number | 7043514 |
| Registration Date | Tuesday, May 2, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 12, 2021 |
| Goods and Services | Pharmaceutical products development; Pharmaceutical research and development, namely, research in the field of gene editing; Pharmaceutical research services; Biomedical research services; Biotechnology research, namely, in the field of genetic editing; Clinical research in the field of gene editing; Drug discovery services; Medical and scientific research in the field of cancer treatment; Medical and scientific research in the field of treatment of rare genetic diseases and disorders; Medical research; Medical research services, namely, for the treatment of cystic fibrosis and lung cancer; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research in the field of genetic editing; Research on the subject of pharmaceuticals, namely, pharmaceuticals to treat genetic disorders, cystic fibrosis and lung cancer; Scientific investigations for medical purposes; Scientific research in the field of oncology; Scientific study and research in the field of oncology; Technical consulting in the field of pharmaceutical studies; Technical research in the field of pharmaceutical studies; Medical and scientific research in the field of genetic engineering, namely, platform gene editing technology; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific research in the field of genetics and genetic engineering; Platform as a service (PAAS) featuring computer software platforms for gene editing |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 4, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | Tuesday, March 20, 2018 |
| First Use In Commerce Date | Tuesday, March 20, 2018 |
| Party Name | Specific Biologics Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Toronto, Ontario M5G0B7 CA |
| Party Name | Specific Biologics Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Toronto, Ontario M5G0B7 CA |
| Party Name | Specific Biologics Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Toronto, Ontario M5G0B7 CA |
| Event Date | Event Description |
| Tuesday, May 2, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, May 2, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Saturday, March 25, 2023 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Friday, March 24, 2023 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Friday, March 10, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, January 17, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 17, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 17, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, January 17, 2023 | ASSIGNED TO LIE |
| Tuesday, January 10, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sunday, July 17, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, July 17, 2022 | NON-FINAL ACTION E-MAILED |
| Sunday, July 17, 2022 | SU - NON-FINAL ACTION - WRITTEN |
| Monday, May 16, 2022 | STATEMENT OF USE PROCESSING COMPLETE |
| Tuesday, May 10, 2022 | USE AMENDMENT FILED |
| Tuesday, May 10, 2022 | TEAS STATEMENT OF USE RECEIVED |
| Thursday, December 16, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, December 16, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, December 16, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, December 7, 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, October 12, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 12, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 22, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, September 9, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 11, 2021 | DIVISIONAL PROCESSING COMPLETE |
| Wednesday, May 19, 2021 | DIVISIONAL REQUEST RECEIVED |
| Monday, August 2, 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, July 7, 2021 | ASSIGNED TO LIE |
| Wednesday, May 19, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, May 19, 2021 | TEAS REQUEST TO DIVIDE RECEIVED |
| Sunday, November 29, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, November 29, 2020 | NON-FINAL ACTION E-MAILED |
| Sunday, November 29, 2020 | NON-FINAL ACTION WRITTEN |
| Saturday, November 28, 2020 | ASSIGNED TO EXAMINER |
| Friday, September 4, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, August 8, 2020 | NEW APPLICATION ENTERED |